Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

Constance Delaby; Charlotte E Teunissen; Kaj Blennow; Daniel Alcolea; Ivan Arisi; Elodie Bouaziz Amar; Anne Beaume; Aurélie Bedel; Giovanni Bellomo; Edith Bigot-Corbel; Maria Bjerke; Marie-Céline Blanc-Quintin; Mercè Boada; Olivier Bousiges; Miles D Chapman; Mari L DeMarco; Mara D'Onofrio; Julien Dumurgier; Diane Dufour-Rainfray; Sebastiaan Engelborghs; Hermann Esselmann; Anne Fogli; Audrey Gabelle; Elisabetta Galloni; Clémentine Gondolf; Frédérique Grandhomme; Oriol Grau-Rivera; Melanie Hart; Takeshi Ikeuchi; Andreas Jeromin; Kensaku Kasuga; Ashvini Keshavan; Michael Khalil; Peter Körtvelyessy; Agnieszka Kulczynska-Przybik; Jean-Louis Laplanche; Piotr Lewczuk; Qiao-Xin Li; Alberto Lleó; Catherine Malaplate; Marta Marquié; Colin L Masters; Barbara Mroczko; Léonor Nogueira; Adelina Orellana; Markus Otto; Jean-Baptiste Oudart; Claire Paquet; Federico Paolini Paoletti; Lucilla Parnetti; Armand Perret-Liaudet; Katell Peoc'h; Koen Poesen; Albert Puig-Pijoan; Isabelle Quadrio; Muriel Quillard-Muraine; Benoit Rucheton; Susanna Schraen; Jonathan M Schott; Leslie M Shaw; Marc Suárez-Calvet; Magda Tsolaki; Hayrettin Tumani; Chinedu T Udeh-Momoh; Lucie Vaudran; Marcel M Verbeek; Federico Verde; Lisa Vermunt; Jonathan Vogelgsang; Jens Wiltfang; Henrik Zetterberg; Sylvain Lehmann

doi:10.1002/alz.12545

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

Constance Delaby, Charlotte E Teunissen, Kaj Blennow, Daniel Alcolea, Ivan Arisi, Elodie Bouaziz Amar, Anne Beaume, Aurélie Bedel, Giovanni Bellomo, Edith Bigot-Corbel, Maria Bjerke, Marie-Céline Blanc-Quintin, Mercè Boada, Olivier Bousiges, Miles D Chapman, Mari L DeMarco, Mara D'Onofrio, Julien Dumurgier, Diane Dufour-Rainfray, Sebastiaan EngelborghsHermann Esselmann, Anne Fogli, Audrey Gabelle, Elisabetta Galloni, Clémentine Gondolf, Frédérique Grandhomme, Oriol Grau-Rivera, Melanie Hart, Takeshi Ikeuchi, Andreas Jeromin, Kensaku Kasuga, Ashvini Keshavan, Michael Khalil, Peter Körtvelyessy, Agnieszka Kulczynska-Przybik, Jean-Louis Laplanche, Piotr Lewczuk, Qiao-Xin Li, Alberto Lleó, Catherine Malaplate, Marta Marquié, Colin L Masters, Barbara Mroczko, Léonor Nogueira, Adelina Orellana, Markus Otto, Jean-Baptiste Oudart, Claire Paquet, Federico Paolini Paoletti, Lucilla Parnetti, Armand Perret-Liaudet, Katell Peoc'h, Koen Poesen, Albert Puig-Pijoan, Isabelle Quadrio, Muriel Quillard-Muraine, Benoit Rucheton, Susanna Schraen, Jonathan M Schott, Leslie M Shaw, Marc Suárez-Calvet, Magda Tsolaki, Hayrettin Tumani, Chinedu T Udeh-Momoh, Lucie Vaudran, Marcel M Verbeek, Federico Verde, Lisa Vermunt, Jonathan Vogelgsang, Jens Wiltfang, Henrik Zetterberg, Sylvain Lehmann

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

92 Downloads (Pure)

Abstract

INTRODUCTION: The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests.

METHODS: We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients.

RESULTS: The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis.

DISCUSSION: This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.

Original language	English
Pages (from-to)	1868-1879
Number of pages	12
Journal	Alzheimer's & Dementia
Volume	18
Issue number	10
Early online date	22 Dec 2021
DOIs	https://doi.org/10.1002/alz.12545
Publication status	Published - Oct 2022

Bibliographical note

Funding Information:
Jean‐Baptiste Oudart is supported by Astrazeneca grant for a research program on EGFR targeted therapy resistance in NSCLC. He received no support for the present manuscript.

Funding Information:
Alberto Lleó is supported by grants from Generalitat de Catalunya (PERIS SLT002/16/00408), Instituto de Salud Carlos III (PI17/01896), Instituto de Salud Carlos III CIBERNED. He received no support for the present manuscript.

Funding Information:
Ashvini Keshavan is supported by the Weston Brain Institute/Selfridges Foundation grant UB170045. She received no support for the present manuscript.

Funding Information:
Jonathan Volgesgang is supported by Clinician Scientist Research Fellowship, German Research Foundation (Deutsche Forschungsgesellschaft, project number: 413501650; 09/01/2019‐02/28/2021); Eric Dorris Memorial Fellowship (McLean Hospital; 07/01/2020‐06/30/2021). He received no support for the present manuscript.

Funding Information:
Marta Marquié is supported by the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII‐Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER‐Una manera de hacer Europa) grant PI19/00335. She received no support for the present manuscript.

Funding Information:
Markus Otto is supported by BMBF, Thierry Latran foundation, EU, DFG. He received no support for the present manuscript.

Funding Information:
Katell Peoc'h is supported by contract with Siemens Healthineers. She received no support for the present manuscript.

Funding Information:
Jens Wiltfang is supported by Federal Ministry of Education and Research (BMBF) State of Lower Saxony; He received no support for the present manuscript.

Funding Information:
Marcel M. Verbeek is supported by the BIONIC project (no. 733050822, which has been made possible by ZonMw within the framework of “Memorabel,” the research and innovation program for dementia, as part of the Dutch national “Deltaplan for Dementia”: zonmw.nl/dementiaresearch), and the CAFÉ project (the National Institutes of Health, USA, grant number 5R01NS104147‐02). The BIONIC project is a consortium of Radboudumc, LUMC, ADX Neurosciences, and University of Rhode Island University. MM Verbeek is also supported by a grant from the Selfridges Group Foundation. He received no support for the present manuscript.

Funding Information:
Michael Khalil received unrestricted research grants from Biogen and Novartis. He received no support for the present manuscript.

Funding Information:
Leslie M. Shaw is supported by NIA for ADNI Biomarker Core, UPENN ADRC Biomarker Corr, MJ Fox PPMI for CSF Biomarker measurements, Roche for IIS study of AD biomarkers. He received no support for the present manuscript.

Funding Information:
Sebastiaan Engelborghs received consulting fees from Biogen, Danone, Eisai, icometrix, Pfizer, Novartis, Nutricia, Roche, and received research funding from ADx Neurosciences and Janssen Pharmaceutica. He received fees as an advisory Boards from Biogen, Danone, Eisai, icometrix, Pfizer, Novartis, Nutricia, Roche. He serves as Secretary‐General of Belgian Neurological Society, Vice‐President of Belgian Dementia Council, ExCo member of European Alzheimer Disease Consortium.

Funding Information:
Lisa Vermunt is supported by Alzheimer Nederland. She received no support for the present manuscript.

Funding Information:
Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018‐02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG‐720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809‐2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF‐21‐831376‐C, #ADSF‐21‐831381‐C and #ADSF‐21‐831377‐C), the Olav Thon Foundation, the Erling‐Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019‐0228), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska‐Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. He received no support for the present manuscript.

Funding Information:
Jonathan M. Schott is supported by the Medical Research Council, Alzheimer's Research UK, Weston Brain Institute, British Heart Foundation, Alzheimer's Association. He received no support for the present manuscript.

Funding Information:
Melanie Hart receives UCLH Biomedical Research Centre support from NIHR (Neurosciences). She received no support for the present manuscript.

Funding Information:
Hayrettin Tumani is supported by Alexion, Bayer, Biogen, Celgene, Genzyme‐Sanofi, Merck, Novartis, Roche, Teva. He received no support for the present manuscript.

Funding Information:
Marc Suárez‐Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677). He also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018‐037478‐I). He received no support for the present manuscript.

Funding Information:
Oriol Grau‐Rivera receives grants from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2017‐33437), and from the Alzheimer's Association Research Fellowship Program (2019‐AARF‐644568). He received no support for the present manuscript.

Publisher Copyright:
© 2021 the Alzheimer's Association

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Keywords

Alzheimer's disease
cerebrospinal fluid biomarkers
clinical report
consensus approach
harmonization

Access to Document

10.1002/alz.12545Licence: CC BY-NC-ND

79042713Final published version, 259 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

Delaby, C., Teunissen, C. E., Blennow, K., Alcolea, D., Arisi, I., Amar, E. B., Beaume, A., Bedel, A., Bellomo, G., Bigot-Corbel, E., Bjerke, M., Blanc-Quintin, M.-C., Boada, M., Bousiges, O., Chapman, M. D., DeMarco, M. L., D'Onofrio, M., Dumurgier, J., Dufour-Rainfray, D., ... Lehmann, S. (2022). Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's & Dementia, 18(10), 1868-1879. https://doi.org/10.1002/alz.12545

@article{6bc9c65bec754fca826535feb89d0f3b,

title = "Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview",

abstract = "INTRODUCTION: The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests.METHODS: We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients.RESULTS: The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis.DISCUSSION: This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.",

keywords = "Alzheimer's disease, cerebrospinal fluid biomarkers, clinical report, consensus approach, harmonization",

author = "Constance Delaby and Teunissen, {Charlotte E} and Kaj Blennow and Daniel Alcolea and Ivan Arisi and Amar, {Elodie Bouaziz} and Anne Beaume and Aur{\'e}lie Bedel and Giovanni Bellomo and Edith Bigot-Corbel and Maria Bjerke and Marie-C{\'e}line Blanc-Quintin and Merc{\`e} Boada and Olivier Bousiges and Chapman, {Miles D} and DeMarco, {Mari L} and Mara D'Onofrio and Julien Dumurgier and Diane Dufour-Rainfray and Sebastiaan Engelborghs and Hermann Esselmann and Anne Fogli and Audrey Gabelle and Elisabetta Galloni and Cl{\'e}mentine Gondolf and Fr{\'e}d{\'e}rique Grandhomme and Oriol Grau-Rivera and Melanie Hart and Takeshi Ikeuchi and Andreas Jeromin and Kensaku Kasuga and Ashvini Keshavan and Michael Khalil and Peter K{\"o}rtvelyessy and Agnieszka Kulczynska-Przybik and Jean-Louis Laplanche and Piotr Lewczuk and Qiao-Xin Li and Alberto Lle{\'o} and Catherine Malaplate and Marta Marqui{\'e} and Masters, {Colin L} and Barbara Mroczko and L{\'e}onor Nogueira and Adelina Orellana and Markus Otto and Jean-Baptiste Oudart and Claire Paquet and Paoletti, {Federico Paolini} and Lucilla Parnetti and Armand Perret-Liaudet and Katell Peoc'h and Koen Poesen and Albert Puig-Pijoan and Isabelle Quadrio and Muriel Quillard-Muraine and Benoit Rucheton and Susanna Schraen and Schott, {Jonathan M} and Shaw, {Leslie M} and Marc Su{\'a}rez-Calvet and Magda Tsolaki and Hayrettin Tumani and Udeh-Momoh, {Chinedu T} and Lucie Vaudran and Verbeek, {Marcel M} and Federico Verde and Lisa Vermunt and Jonathan Vogelgsang and Jens Wiltfang and Henrik Zetterberg and Sylvain Lehmann",

note = "Funding Information: Jean‐Baptiste Oudart is supported by Astrazeneca grant for a research program on EGFR targeted therapy resistance in NSCLC. He received no support for the present manuscript. Funding Information: Alberto Lle{\'o} is supported by grants from Generalitat de Catalunya (PERIS SLT002/16/00408), Instituto de Salud Carlos III (PI17/01896), Instituto de Salud Carlos III CIBERNED. He received no support for the present manuscript. Funding Information: Ashvini Keshavan is supported by the Weston Brain Institute/Selfridges Foundation grant UB170045. She received no support for the present manuscript. Funding Information: Jonathan Volgesgang is supported by Clinician Scientist Research Fellowship, German Research Foundation (Deutsche Forschungsgesellschaft, project number: 413501650; 09/01/2019‐02/28/2021); Eric Dorris Memorial Fellowship (McLean Hospital; 07/01/2020‐06/30/2021). He received no support for the present manuscript. Funding Information: Marta Marqui{\'e} is supported by the Instituto de Salud Carlos III (ISCIII) Acci{\'o}n Estrat{\'e}gica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII‐Subdirecci{\'o}n General de Evaluaci{\'o}n and the Fondo Europeo de Desarrollo Regional (FEDER‐Una manera de hacer Europa) grant PI19/00335. She received no support for the present manuscript. Funding Information: Markus Otto is supported by BMBF, Thierry Latran foundation, EU, DFG. He received no support for the present manuscript. Funding Information: Katell Peoc'h is supported by contract with Siemens Healthineers. She received no support for the present manuscript. Funding Information: Jens Wiltfang is supported by Federal Ministry of Education and Research (BMBF) State of Lower Saxony; He received no support for the present manuscript. Funding Information: Marcel M. Verbeek is supported by the BIONIC project (no. 733050822, which has been made possible by ZonMw within the framework of “Memorabel,” the research and innovation program for dementia, as part of the Dutch national “Deltaplan for Dementia”: zonmw.nl/dementiaresearch), and the CAF{\'E} project (the National Institutes of Health, USA, grant number 5R01NS104147‐02). The BIONIC project is a consortium of Radboudumc, LUMC, ADX Neurosciences, and University of Rhode Island University. MM Verbeek is also supported by a grant from the Selfridges Group Foundation. He received no support for the present manuscript. Funding Information: Michael Khalil received unrestricted research grants from Biogen and Novartis. He received no support for the present manuscript. Funding Information: Leslie M. Shaw is supported by NIA for ADNI Biomarker Core, UPENN ADRC Biomarker Corr, MJ Fox PPMI for CSF Biomarker measurements, Roche for IIS study of AD biomarkers. He received no support for the present manuscript. Funding Information: Sebastiaan Engelborghs received consulting fees from Biogen, Danone, Eisai, icometrix, Pfizer, Novartis, Nutricia, Roche, and received research funding from ADx Neurosciences and Janssen Pharmaceutica. He received fees as an advisory Boards from Biogen, Danone, Eisai, icometrix, Pfizer, Novartis, Nutricia, Roche. He serves as Secretary‐General of Belgian Neurological Society, Vice‐President of Belgian Dementia Council, ExCo member of European Alzheimer Disease Consortium. Funding Information: Lisa Vermunt is supported by Alzheimer Nederland. She received no support for the present manuscript. Funding Information: Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018‐02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG‐720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809‐2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF‐21‐831376‐C, #ADSF‐21‐831381‐C and #ADSF‐21‐831377‐C), the Olav Thon Foundation, the Erling‐Persson Family Foundation, Stiftelsen f{\"o}r Gamla Tj{\"a}narinnor, Hj{\"a}rnfonden, Sweden (#FO2019‐0228), the European Union's Horizon 2020 research and innovation program under the Marie Sk{\l}odowska‐Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. He received no support for the present manuscript. Funding Information: Jonathan M. Schott is supported by the Medical Research Council, Alzheimer's Research UK, Weston Brain Institute, British Heart Foundation, Alzheimer's Association. He received no support for the present manuscript. Funding Information: Melanie Hart receives UCLH Biomedical Research Centre support from NIHR (Neurosciences). She received no support for the present manuscript. Funding Information: Hayrettin Tumani is supported by Alexion, Bayer, Biogen, Celgene, Genzyme‐Sanofi, Merck, Novartis, Roche, Teva. He received no support for the present manuscript. Funding Information: Marc Su{\'a}rez‐Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677). He also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018‐037478‐I). He received no support for the present manuscript. Funding Information: Oriol Grau‐Rivera receives grants from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2017‐33437), and from the Alzheimer's Association Research Fellowship Program (2019‐AARF‐644568). He received no support for the present manuscript. Publisher Copyright: {\textcopyright} 2021 the Alzheimer's Association Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2022",

month = oct,

doi = "10.1002/alz.12545",

language = "English",

volume = "18",

pages = "1868--1879",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "10",

}

Delaby, C, Teunissen, CE, Blennow, K, Alcolea, D, Arisi, I, Amar, EB, Beaume, A, Bedel, A, Bellomo, G, Bigot-Corbel, E, Bjerke, M, Blanc-Quintin, M-C, Boada, M, Bousiges, O, Chapman, MD, DeMarco, ML, D'Onofrio, M, Dumurgier, J, Dufour-Rainfray, D, Engelborghs, S, Esselmann, H, Fogli, A, Gabelle, A, Galloni, E, Gondolf, C, Grandhomme, F, Grau-Rivera, O, Hart, M, Ikeuchi, T, Jeromin, A, Kasuga, K, Keshavan, A, Khalil, M, Körtvelyessy, P, Kulczynska-Przybik, A, Laplanche, J-L, Lewczuk, P, Li, Q-X, Lleó, A, Malaplate, C, Marquié, M, Masters, CL, Mroczko, B, Nogueira, L, Orellana, A, Otto, M, Oudart, J-B, Paquet, C, Paoletti, FP, Parnetti, L, Perret-Liaudet, A, Peoc'h, K, Poesen, K, Puig-Pijoan, A, Quadrio, I, Quillard-Muraine, M, Rucheton, B, Schraen, S, Schott, JM, Shaw, LM, Suárez-Calvet, M, Tsolaki, M, Tumani, H, Udeh-Momoh, CT, Vaudran, L, Verbeek, MM, Verde, F, Vermunt, L, Vogelgsang, J, Wiltfang, J, Zetterberg, H & Lehmann, S 2022, 'Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview', Alzheimer's & Dementia, vol. 18, no. 10, pp. 1868-1879. https://doi.org/10.1002/alz.12545

TY - JOUR

T1 - Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease

T2 - An international overview

AU - Delaby, Constance

AU - Teunissen, Charlotte E

AU - Blennow, Kaj

AU - Alcolea, Daniel

AU - Arisi, Ivan

AU - Amar, Elodie Bouaziz

AU - Beaume, Anne

AU - Bedel, Aurélie

AU - Bellomo, Giovanni

AU - Bigot-Corbel, Edith

AU - Bjerke, Maria

AU - Blanc-Quintin, Marie-Céline

AU - Boada, Mercè

AU - Bousiges, Olivier

AU - Chapman, Miles D

AU - DeMarco, Mari L

AU - D'Onofrio, Mara

AU - Dumurgier, Julien

AU - Dufour-Rainfray, Diane

AU - Engelborghs, Sebastiaan

AU - Esselmann, Hermann

AU - Fogli, Anne

AU - Gabelle, Audrey

AU - Galloni, Elisabetta

AU - Gondolf, Clémentine

AU - Grandhomme, Frédérique

AU - Grau-Rivera, Oriol

AU - Hart, Melanie

AU - Ikeuchi, Takeshi

AU - Jeromin, Andreas

AU - Kasuga, Kensaku

AU - Keshavan, Ashvini

AU - Khalil, Michael

AU - Körtvelyessy, Peter

AU - Kulczynska-Przybik, Agnieszka

AU - Laplanche, Jean-Louis

AU - Lewczuk, Piotr

AU - Li, Qiao-Xin

AU - Lleó, Alberto

AU - Malaplate, Catherine

AU - Marquié, Marta

AU - Masters, Colin L

AU - Mroczko, Barbara

AU - Nogueira, Léonor

AU - Orellana, Adelina

AU - Otto, Markus

AU - Oudart, Jean-Baptiste

AU - Paquet, Claire

AU - Paoletti, Federico Paolini

AU - Parnetti, Lucilla

AU - Perret-Liaudet, Armand

AU - Peoc'h, Katell

AU - Poesen, Koen

AU - Puig-Pijoan, Albert

AU - Quadrio, Isabelle

AU - Quillard-Muraine, Muriel

AU - Rucheton, Benoit

AU - Schraen, Susanna

AU - Schott, Jonathan M

AU - Shaw, Leslie M

AU - Suárez-Calvet, Marc

AU - Tsolaki, Magda

AU - Tumani, Hayrettin

AU - Udeh-Momoh, Chinedu T

AU - Vaudran, Lucie

AU - Verbeek, Marcel M

AU - Verde, Federico

AU - Vermunt, Lisa

AU - Vogelgsang, Jonathan

AU - Wiltfang, Jens

AU - Zetterberg, Henrik

AU - Lehmann, Sylvain

N1 - Funding Information: Jean‐Baptiste Oudart is supported by Astrazeneca grant for a research program on EGFR targeted therapy resistance in NSCLC. He received no support for the present manuscript. Funding Information: Alberto Lleó is supported by grants from Generalitat de Catalunya (PERIS SLT002/16/00408), Instituto de Salud Carlos III (PI17/01896), Instituto de Salud Carlos III CIBERNED. He received no support for the present manuscript. Funding Information: Ashvini Keshavan is supported by the Weston Brain Institute/Selfridges Foundation grant UB170045. She received no support for the present manuscript. Funding Information: Jonathan Volgesgang is supported by Clinician Scientist Research Fellowship, German Research Foundation (Deutsche Forschungsgesellschaft, project number: 413501650; 09/01/2019‐02/28/2021); Eric Dorris Memorial Fellowship (McLean Hospital; 07/01/2020‐06/30/2021). He received no support for the present manuscript. Funding Information: Marta Marquié is supported by the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII‐Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER‐Una manera de hacer Europa) grant PI19/00335. She received no support for the present manuscript. Funding Information: Markus Otto is supported by BMBF, Thierry Latran foundation, EU, DFG. He received no support for the present manuscript. Funding Information: Katell Peoc'h is supported by contract with Siemens Healthineers. She received no support for the present manuscript. Funding Information: Jens Wiltfang is supported by Federal Ministry of Education and Research (BMBF) State of Lower Saxony; He received no support for the present manuscript. Funding Information: Marcel M. Verbeek is supported by the BIONIC project (no. 733050822, which has been made possible by ZonMw within the framework of “Memorabel,” the research and innovation program for dementia, as part of the Dutch national “Deltaplan for Dementia”: zonmw.nl/dementiaresearch), and the CAFÉ project (the National Institutes of Health, USA, grant number 5R01NS104147‐02). The BIONIC project is a consortium of Radboudumc, LUMC, ADX Neurosciences, and University of Rhode Island University. MM Verbeek is also supported by a grant from the Selfridges Group Foundation. He received no support for the present manuscript. Funding Information: Michael Khalil received unrestricted research grants from Biogen and Novartis. He received no support for the present manuscript. Funding Information: Leslie M. Shaw is supported by NIA for ADNI Biomarker Core, UPENN ADRC Biomarker Corr, MJ Fox PPMI for CSF Biomarker measurements, Roche for IIS study of AD biomarkers. He received no support for the present manuscript. Funding Information: Sebastiaan Engelborghs received consulting fees from Biogen, Danone, Eisai, icometrix, Pfizer, Novartis, Nutricia, Roche, and received research funding from ADx Neurosciences and Janssen Pharmaceutica. He received fees as an advisory Boards from Biogen, Danone, Eisai, icometrix, Pfizer, Novartis, Nutricia, Roche. He serves as Secretary‐General of Belgian Neurological Society, Vice‐President of Belgian Dementia Council, ExCo member of European Alzheimer Disease Consortium. Funding Information: Lisa Vermunt is supported by Alzheimer Nederland. She received no support for the present manuscript. Funding Information: Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018‐02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG‐720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809‐2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF‐21‐831376‐C, #ADSF‐21‐831381‐C and #ADSF‐21‐831377‐C), the Olav Thon Foundation, the Erling‐Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019‐0228), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska‐Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. He received no support for the present manuscript. Funding Information: Jonathan M. Schott is supported by the Medical Research Council, Alzheimer's Research UK, Weston Brain Institute, British Heart Foundation, Alzheimer's Association. He received no support for the present manuscript. Funding Information: Melanie Hart receives UCLH Biomedical Research Centre support from NIHR (Neurosciences). She received no support for the present manuscript. Funding Information: Hayrettin Tumani is supported by Alexion, Bayer, Biogen, Celgene, Genzyme‐Sanofi, Merck, Novartis, Roche, Teva. He received no support for the present manuscript. Funding Information: Marc Suárez‐Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677). He also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018‐037478‐I). He received no support for the present manuscript. Funding Information: Oriol Grau‐Rivera receives grants from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2017‐33437), and from the Alzheimer's Association Research Fellowship Program (2019‐AARF‐644568). He received no support for the present manuscript. Publisher Copyright: © 2021 the Alzheimer's Association Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2022/10

Y1 - 2022/10

N2 - INTRODUCTION: The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests.METHODS: We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients.RESULTS: The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis.DISCUSSION: This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.

AB - INTRODUCTION: The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests.METHODS: We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients.RESULTS: The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis.DISCUSSION: This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.

KW - Alzheimer's disease

KW - cerebrospinal fluid biomarkers

KW - clinical report

KW - consensus approach

KW - harmonization

UR - http://www.scopus.com/inward/record.url?scp=85121536885&partnerID=8YFLogxK

U2 - 10.1002/alz.12545

DO - 10.1002/alz.12545

M3 - Article

C2 - 34936194

SN - 1552-5260

VL - 18

SP - 1868

EP - 1879

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 10

ER -

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

Abstract

Bibliographical note

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this